STOCK TITAN

Nurix Therapeutics to Participate in Upcoming Investor Conferences

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Nurix Therapeutics, Inc. (Nasdaq: NRIX) to participate in Stifel Healthcare Conference and Piper Sandler Healthcare Conference in November, with webcasts available on the company's website.
Positive
  • Participation in healthcare conferences indicates the company's commitment to investor relations and transparency.
Negative
  • None.

SAN FRANCISCO, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with hematologic malignancies and solid tumors, today announced that Arthur T. Sands, M.D., Ph.D., Nurix’s president and chief executive officer, will participate in the following conferences in November:

  • Stifel Healthcare Conference
    Fireside chat: Tuesday, November 14, 2023, from 4:45 – 5:15 p.m. ET
  • Piper Sandler Healthcare Conference
    Fireside chat: Wednesday, November 29, 2023, from 3:00 – 3:25 p.m. ET

The events will be webcast live and may be accessed via a link in the Investors section of the Nurix website under Events and Presentations. Archived copies of the webcasts will be available on the Nurix website for approximately 30 days after the event.

About Nurix Therapeutics, Inc.

Nurix Therapeutics is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of medicines based on the modulation of cellular protein levels as a novel treatment approach for cancer and other challenging diseases. Leveraging extensive expertise in E3 ligases together with proprietary DNA-encoded libraries, Nurix has built DELigase, an integrated discovery platform, to identify and advance novel drug candidates targeting E3 ligases, a broad class of enzymes that can modulate proteins within the cell. Nurix’s drug discovery approach is to either harness or inhibit the natural function of E3 ligases within the ubiquitin-proteasome system to selectively decrease or increase cellular protein levels. Nurix’s wholly owned, clinical stage pipeline includes targeted protein degraders of Bruton’s tyrosine kinase, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene B, an E3 ligase that regulates activation of multiple immune cell types including T cell and NK cells. Nurix is headquartered in San Francisco, California. For additional information visit http://www.nurixtx.com.

Contacts: 

Investors 
Silinda Neou 
Nurix Therapeutics 
ir@nurixtx.com 

Elizabeth Wolffe, Ph.D. 
Wheelhouse Life Science Advisors 
lwolffe@wheelhouselsa.com 

Media 
Aljanae Reynolds 
Wheelhouse Life Science Advisors 
areynolds@wheelhouselsa.com 


FAQ

What conferences will Nurix Therapeutics, Inc. participate in November?

Nurix Therapeutics, Inc. will participate in the Stifel Healthcare Conference and Piper Sandler Healthcare Conference in November.

Who will represent Nurix Therapeutics, Inc. at the conferences?

Arthur T. Sands, M.D., Ph.D., Nurix’s president and chief executive officer, will represent the company at the conferences.

Where can the webcasts of the events be accessed?

The webcasts may be accessed via a link in the Investors section of the Nurix website under Events and Presentations.

How long will the archived copies of the webcasts be available?

Archived copies of the webcasts will be available on the Nurix website for approximately 30 days after the event.

Nurix Therapeutics, Inc.

NASDAQ:NRIX

NRIX Rankings

NRIX Latest News

NRIX Stock Data

1.39B
69.46M
1.45%
98.43%
13.56%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
SAN FRANCISCO